Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

NCT05164770 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

160

Enrollment

OTHER_GOV

Sponsor class

Conditions

High Grade B-Cell Lymphoma, Not Otherwise Specified
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
Diffuse Large B Cell Lymphoma
B-cell Non Hodgkin Lymphoma
Mantle Cell Lymphoma

Interventions

DRUG: Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
DRUG: R-CHOP; R-DA-EPOCH; R-HD MTX

Sponsor

Shandong Provincial Hospital